These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

959 related articles for article (PubMed ID: 29192287)

  • 1. Next generation antibody drugs: pursuit of the 'high-hanging fruit'.
    Carter PJ; Lazar GA
    Nat Rev Drug Discov; 2018 Mar; 17(3):197-223. PubMed ID: 29192287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies and challenges for the next generation of therapeutic antibodies.
    Beck A; Wurch T; Bailly C; Corvaia N
    Nat Rev Immunol; 2010 May; 10(5):345-52. PubMed ID: 20414207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homogeneously modified immunoglobulin domains for therapeutic application.
    Liu T; Du J; Luo X; Schultz PG; Wang F
    Curr Opin Chem Biol; 2015 Oct; 28():66-74. PubMed ID: 26117722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Next-Generation Techniques for Discovering Human Monoclonal Antibodies].
    Lushova AA; Biazrova MG; Prilipov AG; Sadykova GK; Kopylov TA; Filatov AV
    Mol Biol (Mosk); 2017; 51(6):899-906. PubMed ID: 29271955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Progress in the study of Her2-targeted cancer therapeutic antibodies].
    Chang L; Li CH; Gao J
    Yao Xue Xue Bao; 2015 May; 50(5):516-20. PubMed ID: 26234129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Engineering Antibodies as Drugs: Principles and Practice].
    Lugovskoy AA
    Mol Biol (Mosk); 2017; 51(6):886-898. PubMed ID: 29271954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The current status and prospects of antibody engineering for therapeutic use: focus on glycoengineering technology.
    Niwa R; Satoh M
    J Pharm Sci; 2015 Mar; 104(3):930-41. PubMed ID: 25583555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bispecific Antibodies and Antibody-Drug Conjugates for Cancer Therapy: Technological Considerations.
    Shim H
    Biomolecules; 2020 Feb; 10(3):. PubMed ID: 32111076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of action of therapeutic monoclonal antibodies: promises and pitfalls of in vitro and in vivo assays.
    Golay J; Introna M
    Arch Biochem Biophys; 2012 Oct; 526(2):146-53. PubMed ID: 22387378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody fragments for controlled delivery of therapeutic agents.
    Verhoeyen ME; van der Logt CP; Beggs TS; Davis PJ
    Biochem Soc Trans; 1995 Nov; 23(4):1067-73. PubMed ID: 8654683
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 1, monoclonal antibodies, antibody-drug conjugates and bispecific T-cell engagers.
    Paci A; Desnoyer A; Delahousse J; Blondel L; Maritaz C; Chaput N; Mir O; Broutin S
    Eur J Cancer; 2020 Mar; 128():107-118. PubMed ID: 32037061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Precision medicine in clinical oncology: the journey from IgG antibody to IgE.
    Fazekas-Singer J; Singer J; Jensen-Jarolim E
    Curr Opin Allergy Clin Immunol; 2020 Jun; 20(3):282-289. PubMed ID: 32349107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody Engineering & Therapeutics 2015: The Antibody Society's annual meeting December 7-10, 2015, San Diego, CA.
    Parren PW; Burton DR; Bradbury A; Huston JS; Carter PJ; Veldman T; Chester KA; Larrick JW; Alfenito MR; Scott JK; Weiner LM; Adams GP; Reichert JM
    MAbs; 2015; 7(6):981-8. PubMed ID: 26421752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The coming of age of engineered multivalent antibodies.
    Nuñez-Prado N; Compte M; Harwood S; Álvarez-Méndez A; Lykkemark S; Sanz L; Álvarez-Vallina L
    Drug Discov Today; 2015 May; 20(5):588-94. PubMed ID: 25757598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unlocking the potential of bispecific ADCs for targeted cancer therapy.
    Zeng H; Ning W; Liu X; Luo W; Xia N
    Front Med; 2024 Aug; 18(4):597-621. PubMed ID: 39039315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics international conferences and the 2012 Annual Meeting of The Antibody Society: December 3-6, 2012, San Diego, CA.
    Klöhn PC; Wuellner U; Zizlsperger N; Zhou Y; Tavares D; Berger S; Zettlitz KA; Proetzel G; Yong M; Begent RH; Reichert JM
    MAbs; 2013; 5(2):178-201. PubMed ID: 23575266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal Antibodies, Bispecific Antibodies and Antibody-Drug Conjugates in Oncohematology.
    Mihăilă RG
    Recent Pat Anticancer Drug Discov; 2020; 15(4):272-292. PubMed ID: 32981510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving the efficacy of antibody-based cancer therapies.
    Carter P
    Nat Rev Cancer; 2001 Nov; 1(2):118-29. PubMed ID: 11905803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging new therapeutic antibody derivatives for cancer treatment.
    Jin S; Sun Y; Liang X; Gu X; Ning J; Xu Y; Chen S; Pan L
    Signal Transduct Target Ther; 2022 Feb; 7(1):39. PubMed ID: 35132063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Next Generation Antibody Therapeutics Using Bispecific Antibody Technology].
    Igawa T
    Yakugaku Zasshi; 2017; 137(7):831-836. PubMed ID: 28674296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.